Clinical Trial Update: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 [Phase 2]

View source ↗

Summary

Update on a Phase 2 study of disitamab vedotin in HER2-expressing solid tumors, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING